Modern Retina Staff

Border zone lifetime gradient correlated with growth rate over 5 years

Varicella vaccine drove the largest risk reduction in a 5-vaccine, multi-million-patient analysis

Three cases illustrate how next-generation anti-VEGF agents are extending treatment intervals and improving durability across retinal vascular disease.

New IGF-1R antibody Lumvoa receives FDA nod for active and chronic thyroid eye disease, offering rapid proptosis relief and diplopia improvement.

A randomized trial found that 8 weeks of daily use of the Calm Health app significantly improved mental health outcomes in adults with non-infectious uveitis.

A prospective pilot study finds focal photopic microperimetry may detect cone-mediated losses that lesion size and visual acuity do not reflect.

A retrospective study identifies thin choroid as the key factor behind ungradable ultrawidefield green-light fundus autofluorescence images in geographic atrophy.

The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.

A propensity-matched retrospective analysis of more than 920,000 adults finds a 30% higher risk of incident uveitis following human papillomavirus infection.

SOL-1 results show intravitreal axitinib hydrogel delivered superior vision maintenance and anatomic outcomes through 52 weeks.

The group recommends more precise language such as “physicians” and “clinicians” to reflect medicine’s humanistic and professional responsibilities.

A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.

A panel of retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301. Which emerging treatments are you most interested in?

A panel of retina experts discussed the challenges presented in the management of DME. Which do you think is the biggest of these challenges?

A panel of retina specialists weighed in on the dosing intervals when using of faricimab for the treatment of neovascular AMD in the clinical practice setting. Do you agree with them?

A panel of esteemed retina specialists recently delved into innovative therapies for neovascular age-related macular degeneration and diabetic macular edema, focusing on personalized treatment, telemedicine, and the ongoing quest for advancements.

Nominations for the 2023 awards will close July 31, 2023.

A poll for retina specialists: Let us know if you will attend the 14th annual Congress on Controversies in Ophthalmology.

A poll for retina specialists: Let us know if you will be logging on for this annual Bascom Palmer Eye Institute symposium, which will be held virtually on February 10 and 11, 2023.

Coordinated by the International Agency for the Prevention of Blindness (IAPB), the international day of awareness is a reminder to "love your eyes."

A poll for retina specialists regarding their attendance at the 2022 American Society of Retina Specialists 40th Annual Scientific Meeting in New York City, New York. This poll is now closed.

According to the ALOFT study, patients demonstrate improved long-term vision in real-world setting after wet AMD conversion compared to current standard of care.

Dr. Stacy Pineles discusses the additional degree opportunities within the residency program at the Jules Stein Eye Institute at UCLA.

At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

NGM621 is a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy secondary to age-related macular degeneration.

Dr. Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DME resolution.

Cleveland Eye Bank Foundation (CEBF) will feature nine researchers from three eye institutions on February 15, from 3 to 5 pm Eastern, for its second annual virtual vision research symposium.

Ted Leng, MD, discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.

Researchers at the University of Virginia School of Medicine have made a discovery linking lupus, a potentially debilitating autoimmune disorder, and macular degeneration, a leading cause of blindness.

Under terms of the agreement, ImprimisRx to assume full responsibility for US sales and marketing activities for Dexycu.